Search

Highlights from the SWG

Impactful activitiesSymposium at EHA2023The SWG held a symposium on ‘2. 0 diagnostics in hematology: the role of AI’ at the EHA2023 Congress. EHA2023 took place from June 8–11, 2023, in Frankfurt, Germany.

Read more

EHA-AAH Balkan Hematology Tutorial 2022

EHA is joined forces with the Albanian Association of Hematology (AAH) to organize the EHA-AAH Balkan Hematology Tutorial.

Read more

2013 & before

2013
EHA-SWG Scientific Meeting on Thrombocytopenia and Disorders of Platelet Function
September 27-29, 2013 | Lisbon, Portugal

EHA-ROHS-RSH Tutorial on Bone Marrow Transplantation
July 5-7, 2013 | Saint Petersburg, Russia

EHA Tutorial on Lymphoma
May 24-26, 2013 | Cape Town, South Africa

EHA-TSH Tutorial on Chronic Myeloproliferative…

Read more

Selected EMA news

Most of EHA’s regulatory activities focus on collaboration with the European Medicines Agency (EMA).

Read more

EHA-LSHBT Virtual Hematology Updates, a Successful Course Tailored for the Region!

March – October 2021

In a series of six webinar courses chairs Gianluca Gaidano (EHA) and Ali Taher (LSHBT) were joined by several experts that gave lectures and interactive patient cases to practitioners who manage patients with benign and hematologic malignancies.…

Read more

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…

Read more

SWG Educational Activities

During the annual meeting of EHA, a scientific session was organized: “Mesenchymal stromal cells: guardians of tissue homeostasis”.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more